The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...

Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain ...

The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...

A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...

Greek-American Pfizer CEO Dr Albert Bourla faced an unwelcoming reception at the White House during an event celebrating ...

The CEO of Pfizer received loud boos when he was introduced by Donald Trump at a Black History Month event at the White House ...

President Donald Trump's introduction of a Pfizer executive at the White House Wednesday was met with a roar of boos from the crowd.

The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover ...

As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...

The stock has averaged annual growth of 6.3% during the past five years, and its dividend has grown, too, from $1 per share in 2018 to $1.73. There's a lot to like about VICI, so learn more about it ...

Valentina Dabos, lead author of the tracker, said in a statement that the consequences of bankruptcies in healthcare "can be ...